VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the “Firm”) (CSE: AGRA) (Frankfurt: PU30) (OTCPK: AGFAF), a growth-oriented and diversified firm targeted on the worldwide hashish trade, is happy to announce that its wholly owned subsidiary, Farmako GmbH (“Farmako”), has carried out the primary industrial import of hashish extracts from Poland to Germany, which is the biggest medical hashish market in Europe. The extracts have been produced based on the best requirements by Pharmacann Polska Sp. z o.o., an EU GMP-certified hashish firm and a part of PHCANN Worldwide (“PHCANN Worldwide” or the “Collaborator”).
Launched underneath Farmako’s model, the extracts are produced by PHCANN Worldwide’s subsidiaries from chosen hybrid hashish flowers grown underneath GACP – EU GMP indoor circumstances. The hashish is grown utterly with out the usage of pesticides and is extracted based on highest trade requirements underneath strict high quality management on the EU GMP facility. With the launch of the extracts, Farmako strengthens its place as provider with a complete portfolio within the medical hashish market – from flowers, extracts and isolate to testkits for pharmacies.
The general German medical hashish market is presently characterised by a substantial variety of wholesalers and producers that supply all types of flower merchandise – typically the identical merchandise underneath totally different names – which could be complicated for medical doctors and sufferers. Extracts provide an answer with their standardized cannabinoid concentrations and allow a managed and fixed treatment for sufferers. Nonetheless, the medical hashish extracts market is small and its development has been impeded by excessive costs, which traditionally has discouraged sufferers, medical doctors and insurance coverage corporations from utilizing them. Farmako desires to alter this by offering its merchandise at reasonably priced costs to additional set up extracts as acknowledged hashish treatment.
Individually, Farmako has not too long ago signed a big wholesale contract for its THC testkits with a hashish producer that may provide the testkits along with their very own hashish merchandise. This association additional emphasizes Farmako’s place as dependable trade companion.
Extra particulars on Farmako’s merchandise could be discovered within the part for medical employees on Farmako’s web site at www.farmako.de/en/.
“Towards all odds – that’s what we most likely must say with some self-irony. It took us for much longer than anticipated to launch these merchandise, and it was not a straight-forward street in any respect, however we’ve all labored onerous to clear the way in which, and our companion PHCANN Worldwide has proven spectacular persistence and above all a really excessive stage of professionalism. The medical hashish market in Germany has modified, and it’s not solely about offering merchandise, particularly in relation to flowers, the place the market even reveals some tendency of oversupply. With PHCANN Worldwide we wish to work on merchandise at extremely aggressive costs which are patient-focused and assist make extracts a necessary a part of an reasonably priced medical hashish remedy – not just for self-payers or non-public sufferers, however for all sufferers,” mentioned Katrin Eckmans, Managing Director of Farmako GmbH.
“The staff at Farmako continues to ship. This association with PHCANN Worldwide to create Farmako-branded extracts and set up a brand new provide channel from Poland to Germany is a superb achievement. I’m very pleased with Katrin and her employees,” mentioned Elise Coppens, Chief Government Officer and Director of Agra Ventures. “Along with the cope with PHCANN Worldwide, the Farmako staff has landed yet one more contract to increase the distribution of its proprietary THC testkits. On behalf of AGRA’s administration staff, I’m proud of these developments and stay up for the continuation of Farmako’s evolution,” added Ms. Coppens.
About PHCANN Worldwide
PHCANN Worldwide is a pharmaceutical firm that applies world requirements within the manufacturing of cannabis-based pharmaceutical extracts and closing pharmaceutical varieties. Utilizing the Israeli, Canadian and US market expertise, their mission is to make sure the provision of merchandise containing cannabinoids of pure origin whereas sustaining strictly managed pharmaceutical high quality and to disseminate information about its medicinal use. For extra data please go to: www.phcann.pl.
Farmako GmbH is a GDP licensed pharmaceutical wholesaler, specializing in medical hashish and aiming at facilitating entry to dependable cannabinoid remedy to sufferers with a excessive burden of struggling in addition to offering environment friendly help to healthcare professionals: by way of truthful costs, dependable product high quality and skill to produce in addition to environment friendly service. It already distributes medical hashish to pharmacies in Germany since March 2019 and is totally licensed in the UK. Farmako is a completely owned subsidiary of Agra Ventures Ltd. For extra data please go to: www.farmako.de/en/.
About Agra Ventures Ltd.
Agra Ventures is a growth-oriented and diversified firm targeted on the worldwide hashish trade. The corporate is devoted to the cultivation, distribution and advertising and marketing of high-quality hashish and cannabis-infused merchandise worldwide. Agra Ventures’ main asset in Canada is Boundary Bay Hashish situated in Delta, BC, which is without doubt one of the largest hashish greenhouse services targeted on the cost-optimized cultivation of high-potency hashish. Overseas, the corporate’s wholly owned subsidiary, Farmako GmbH, is concentrated on changing into Europe’s main distributor of medical hashish. Farmako presently has energetic product distribution operations in Germany and is totally licensed in the UK.
ON BEHALF OF THE BOARD OF DIRECTORS
Nick Kuzyk, Investor Relations
E: [email protected]
T: (800) 783-6056
The CSE and Data Service Supplier have not reviewed and does not settle for duty for the accuracy or adequacy of this launch.
Ahead-looking Data Cautionary Assertion
Besides for statements of historic truth this information launch incorporates sure “forward-looking data” inside the that means of relevant securities regulation. Ahead-looking data is steadily characterised by phrases such as “plan” “count on” “mission” “intend” “consider” “anticipate” “estimate” and different comparable phrases or statements that sure occasions or circumstances “could” or “will” happen. Ahead-looking statements are based mostly on the opinions and estimates at the date the statements are made and are topic to a wide range of dangers and uncertainties and different elements that would trigger precise occasions or outcomes to vary materially from these anticipated within the forward-looking statements together with however not restricted to delays or uncertainties with regulatory approvals together with that of the CSE. There are uncertainties inherent in forward-looking data together with elements past the Firm’s management. There are not any assurances that the enterprise plans for Agra Ventures described in this information launch will come into impact on the phrases or timeframe described herein. The Firm undertakes no obligation to replace forward-looking data if circumstances or administration’s estimates or opinions ought to change besides as required by regulation. The reader is cautioned to not place undue reliance on forward-looking statements. Extra data figuring out dangers and uncertainties that would have an effect on monetary outcomes is contained within the Firm’s filings with Canadian securities regulators which are out there at www.sedar.com.
SOURCE: Agra Ventures Ltd.